Success Metrics

Active Trials
3(75%)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(4)

Detailed Status

Recruiting3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

not_yet_recruiting125%
recruiting375%

Recent Activity

3 active trials
Showing 4 of 4
recruitingphase_1

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

NCT06484790
recruitingphase_1

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

NCT06478251
recruitingphase_1

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

NCT06484556
not_yet_recruitingphase_1

NW-301 TCR-T in Patients With Advanced Solid Tumor

NCT06956261

Clinical Trials (4)

Showing 4 of 4 trials
NCT06484790Phase 1

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Recruiting
NCT06478251Phase 1

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Recruiting
NCT06484556Phase 1

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Recruiting
NCT06956261Phase 1

NW-301 TCR-T in Patients With Advanced Solid Tumor

Not Yet Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4